Here I report the first findings of consistently high, long-duration efficacy of IR3535 (ethyl butyl acetyl aminopropionate) formulations in the United States. I tested novel, controlled-release formulations of IR3535, at 10% in lotion and at 20% in pump spray and aerosol, against mosquitoes in the field and blacklegged ticks in the laboratory. These were also the first studies to be conducted under the authority of the U.S. Environmental Protection Agency’s Human Studies Rule of 2006, and the protocols underwent science and ethics reviews by five entities. IR3535 is better known in Europe than in North America, having been marketed in the United States only more recently, and there are comparatively few publications on its efficacy. I began with pretrial studies of dosing behavior to compute formula-specific mean dosing rates for the subsequent efficacy trials. Dosing rates were lower than the 1 ml/600 cm rate commonly used to quantify efficacy. Complete protection times ranged from 7.1 to 10.3 h for mosquitoes and from 9.1 to 12.2 h for blacklegged ticks. Long protection duration resulted in many cases being truncated by darkness or eventual subject withdrawal, which suggests that actual protection times were probably greater.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 45 • No. 4